ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Renfro, Lindsay A ^a   Grothey, Axel ^a   Xue, Yuan ^b   Saltz, Leonard B ^c   André, Thierry ^d,e   Twelves, Chris ^f   Labianca, Roberto ^g   Allegra, Carmen J ^h   Alberts, Steven R ^a   Loprinzi, Charles L ^a   Yothers, Greg ⁱ   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HÔPITAL SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g Ospedale Papa Giovanni XXIII   (Italy)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE;

ACCENT BASED WEB CALCULATOR; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CALCULATOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; COLON CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUANTITATIVE STUDY; TUMOR LOCALIZATION; TUMOR VOLUME; WEB BROWSER; CANCER STAGING; CLINICAL PRACTICE; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; INTERNET; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SOFTWARE; TRENDS; TUMOR RECURRENCE; UNITED STATES;

AGED; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERNET; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOFTWARE; UNITED STATES;

EID: 84930732973     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju333     Document Type: Article

References (24)

1. CDC - Colorectal Cancer Statistics. Centers for Disease Control and Prevention. Atlanta, GA. Available at: http://www.cdc.gov/cancer/colorectal/statistics. Accessed March 22, 2013.
2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
3. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116.
4. Schmoll H-J, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2006;25(1):102-109.
5. Yothers G, O'Connell M, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768-3774.
6. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806.
7. Colorectal Cancer: Prediction Tools. Memorial Sloan-Kettering Cancer Center. New York, NY. Available at: http://www.mskcc.org/cancer-care/adult/colorectal/prediction-tools. Accessed March 22, 2013.
8. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008;26(3):380-385.
9. Weiser MR, Gönen M, Chou JF, et al. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011;29(36):4796-4801.
10. Adjuvant! Online. Adjuvant! Inc. Available at: http://www.adjuvantonline.com/index.jsp. Accessed March 22, 2013.
11. Gill S, Loprinzi C, Kennecke H, et al. Prognostic web-based models for stage II and III colon cancer. Cancer. 2011;117(18):4155-4165.
12. th ed. New York: Springer; 2010.
13. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664-8670.
14. Sargent DJ, Shi Q, Yothers G, et al. Two or three year disease free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803. Eur J Cancer. 2011;47(7):990-996.
15. Little RJ, Rubin D. Statistical Analysis with Missing Data. New York, NY: John Wiley and Sons, Inc.; 2002.
16. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2010.
17. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
18. Steyerberg EW. Clinical Prediction Models. New York: Springer; 2010.
19. R Development Core Team. R: A language and environment for statistical computing (http://www.R-project.org). Vienna: R Foundation for Statistical Computing; 2008.
20. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11-16.
21. Renfro LA, Shi Q, Sargent DJ. Mining the ACCENT database: a review and update. Chinese Clin Oncol. 2013;2(2):1-8.
22. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup phase III trial N0147. J Clin Oncol. 2010;28 suppl 18. Abstract CRA3507.
23. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225-1233.
24. Taieb J, Puig PL, Bedenne L. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther. 2008;8(2):183-189.